Aura Biosciences begins dosing in belzupacap sarotalocan phase 1 trial in NMIBC

TAGS

Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its first virus-like drug conjugate (VDC) — belzupacap sarotalocan for the treatment of non-muscle invasive bladder cancer (NMIBC).

According to the NASDAQ-listed clinical-stage biotech company, the early-stage multi-center, open label study is likely to take in nearly 23 adults having the type of bladder cancer.

The phase 1 clinical trial of belzupacap sarotalocan will evaluate the safety and tolerability of the virus-like drug conjugate as a single agent.

See also  New US biotech company Twentyeight-Seven Therapeutics launched with $65m funding

The primary endpoint of the early-stage non-muscle invasive bladder cancer clinical trial is the incidence and severity of treatment-associated adverse events and serious adverse events and the occurrence of dose-limiting toxicities.

Aura Biosciences expects to release initial phase 1 data of the belzupacap sarotalocan clinical trial in 2023. In June 2022, the virus-like drug conjugate was issued fast track designation from the US Food and Drug Administration (FDA).

See also  Zydus Lifesciences gets FDA approval for Bortezomib for Injection

Dr. Cadmus Rich — Aura Biosciences Chief Medical Officer and Head of research and development said: “Dosing of the first patient in this Phase 1 study is an exciting key milestone both for Aura and for the field of urologic oncology, as approximately 70% of patients with bladder cancer globally are diagnosed early with NMIBC.

See also  AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio

“There have been no major advances in the early treatment of NMIBC in over two decades. We look forward to presenting initial Phase 1 data in 2023 and advancing the development of a potential new therapeutic option for patients with a high unmet medical need.”

CATEGORIES
TAGS
Share This